Abstract
Wnt signaling plays an important role in cancer. Signaling is initiated by binding of Wnt ligands to Frizzled cell surface receptors and results in signaling via one of three pathways, the canonical Wnt pathway, which is the best characterized in both normal tissues and in cancer, and two non-canonical Wnt pathways, the Ca2+-dependent and the PCP pathways. Canonical Wnt signaling results in β-catenin accumulation in the cytoplasm, translocation into the nucleus and activation of transcription of Wnt target genes including the c-Myc oncogene. Some cancer types, including colorectal cancer, have mutations in APC and Axin, which are involved in β-catenin phosphorylation, such that the canonical pathway is constitutively active. Few studies have investigated the role non-canonical Wnt signaling in cancer, or of Wnt signaling on tumor stromal cells. Wnt overexpression is observed in tumor stroma, as is overexpression of the Wnt pathway inhibitors, secreted Frizzled-related proteins and Dickkopf proteins. Interactions between epithelial cells and stromal cells have been observed to activate Wnt signaling in both cell types. Wnt signaling is also observed in tumor blood vessels and is likely to be activated by signals from tumor cells. Current cancer therapies focus on interfering with canonical Wnt signaling in the tumor cells. Future therapeutic targets for interfering with Wnt signaling include cell surface receptors such as the RYK and Ror2 receptors and secreted signaling molecules, which mediate signaling between cancer cells and the stromal environment.
Keywords: Wnt signaling, RYK, Ror2, stroma, cancer therapy
Current Cancer Drug Targets
Title: Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Volume: 8 Issue: 6
Author(s): Maria L. Macheda and Steven A. Stacker
Affiliation:
Keywords: Wnt signaling, RYK, Ror2, stroma, cancer therapy
Abstract: Wnt signaling plays an important role in cancer. Signaling is initiated by binding of Wnt ligands to Frizzled cell surface receptors and results in signaling via one of three pathways, the canonical Wnt pathway, which is the best characterized in both normal tissues and in cancer, and two non-canonical Wnt pathways, the Ca2+-dependent and the PCP pathways. Canonical Wnt signaling results in β-catenin accumulation in the cytoplasm, translocation into the nucleus and activation of transcription of Wnt target genes including the c-Myc oncogene. Some cancer types, including colorectal cancer, have mutations in APC and Axin, which are involved in β-catenin phosphorylation, such that the canonical pathway is constitutively active. Few studies have investigated the role non-canonical Wnt signaling in cancer, or of Wnt signaling on tumor stromal cells. Wnt overexpression is observed in tumor stroma, as is overexpression of the Wnt pathway inhibitors, secreted Frizzled-related proteins and Dickkopf proteins. Interactions between epithelial cells and stromal cells have been observed to activate Wnt signaling in both cell types. Wnt signaling is also observed in tumor blood vessels and is likely to be activated by signals from tumor cells. Current cancer therapies focus on interfering with canonical Wnt signaling in the tumor cells. Future therapeutic targets for interfering with Wnt signaling include cell surface receptors such as the RYK and Ror2 receptors and secreted signaling molecules, which mediate signaling between cancer cells and the stromal environment.
Export Options
About this article
Cite this article as:
Macheda L. Maria and Stacker A. Steven, Importance of Wnt Signaling in the Tumor Stroma Microenvironment, Current Cancer Drug Targets 2008; 8 (6) . https://dx.doi.org/10.2174/156800908785699324
DOI https://dx.doi.org/10.2174/156800908785699324 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics A Constrained Probabilistic Matrix Decomposition Method for Predicting miRNA-disease Associations
Current Bioinformatics Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size
Current Drug Delivery Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Extraction of Triacylglycerols and Fatty Acids Using Supercritical Fluids - Review
Current Analytical Chemistry Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity
Current Topics in Medicinal Chemistry Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer
Current Topics in Medicinal Chemistry Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry MicroRNA Dysregulation in Gastric Cancer
Current Pharmaceutical Design Novel Insights Into c-Src
Current Pharmaceutical Design Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Patent Selections :
Recent Patents on Biomarkers